Otonomy is a biopharmaceutical company. Co. engages in the application of drug delivery technology to the ear, which addresses medical needs. Co.'s product candidates include: OTIVIDEX, a steroid in development for the treatment of Meniere's disease; OTO-313, a selective N-Methyl-D-Aspartate receptor antagonist in development for the treatment of tinnitus; OTO-413, a sustained exposure formulation of brain-derived neurotrophic factor in development for the repair of cochlear synaptopathy, an underlying pathology in age-related and noise-induced hearing loss that manifests as speech-in-noise hearing difficulty (problem understanding speech in a noisy setting); OTO-825; OTO-510; and OTO-6XX. The OTIC stock yearly return is shown above.
The yearly return on the OTIC stock yearly return page and across the coverage universe of our site,
is a measure of the annual return over the calendar year 2017 for the given stock.
When performing this calculation it is important to factor in dividends, because a financial instrument's annual return is
more than just the change in price if that instrument pays a dividend or coupon.
One way to factor dividends into the return is simply to count them as cash — we don't do
that here. Instead, our website aims to empower investors
by performing the OTIC annual return calculation with any dividends reinvested as applicable (on ex-dates).
|